Politics
TrumpRx Leads To Biggest Drop In Drug Prices In Over 60 Years
Prescription drug prices posted their steepest year-over-year decline in more than six decades in July, handing the Trump White House a major economic talking point as it pushes its America First drug-pricing agenda.
Prices for prescription drugs fell 3.1% over the 12 months ending in July, the largest annual drop since March 1963, according to new Bureau of Labor Statistics data.
The broader medicinal drug category fell 2.7% over the same period, the biggest annual decline on record.
The White House quickly pointed to President Donald Trump’s drug-pricing push, including agreements with pharmaceutical companies and the launch of TrumpRx, as evidence that the administration’s policies are starting to deliver real savings.
“No president in modern history has been able to drastically reduce prescription drug prices across the board except for President Trump,” White House spokesman Kush Desai said in an email. “This is a direct result of the President’s willingness to push the envelope with bold policies that actually put Americans and America First.”
One of the biggest areas of focus has been GLP-1 weight-loss drugs, which have carried price tags topping $1,000 per month through insurers.
TrumpRx, launched earlier this year, offers some GLP-1 drugs for as little as $150 for a starting dose.
Under a separate Medicare pilot program launched in July, Novo Nordisk and Eli Lilly agreed to charge the federal government $245 per month for Wegovy, Zepbound and Foundayo.
Trump and the drugmakers began negotiating last year, with the broad outlines of the agreements announced in November.
“In a matter of months, we got up and running these discounts in a way that they were meaningful for American patients,” said a White House official, speaking on the condition of anonymity because administration staff are not authorized to speak publicly.
The decline comes as prescription drug prices have been sliding sharply for months.
POLL: Will You Support Trump And His Candidates In The Midterms?
Renaissance Macro said prices have fallen at a seasonally adjusted annual rate of 6.6% over the past six months, calling it “the sharpest six month drop on record.”
The investment research firm celebrated the July numbers with a simple reaction.
“Just what the doctor ordered!” Renaissance Macro posted to X on Wednesday.
TrumpRx is working.
Prescription drug prices are FALLING because President @realDonaldTrump is cutting out the middlemen, lowering costs, and putting American patients FIRST. 🇺🇸 pic.twitter.com/gfWNyoFUEo
— Trump War Room (@TrumpWarRoom) August 11, 2026
Not everyone agrees on what deserves the credit.
Some health policy experts argue that Medicare drug negotiations created under former President Joe Biden’s Inflation Reduction Act are also playing a role.
The first negotiated prices under that law took effect at the beginning of 2026 and currently cover 10 widely used prescription drugs.
Richard Frank, a senior fellow at the Brookings Institution and professor emeritus of health economics at Harvard University, said he believes those policies are more likely to be driving the decline.
“If I was a betting guy on what mattered most, it would be probably stuff around the Inflation Reduction Act,” Frank said, adding that Trump’s efforts “wouldn’t be where I’d place my money.”
Vanderbilt University health policy professor Stacie Dusetzina similarly argued that Medicare negotiations are a more plausible contributor than TrumpRx because the negotiated medicines are
widely used.
RELATED: JUST IN: Americans Get Welcome Financial News As Trump Economy Defies Experts
She said those drugs “and their prices would likely be reflected in the prescription drug index,” while TrumpRx currently covers “a limited number of branded drugs,” and “aside from GLP1s, they may not be high enough volume to be included.”
The Trump administration disputes the idea that the Biden-era law deserves most of the credit, pointing out that the policy took years to take effect while the current White House has moved quickly to strike new pricing agreements.
Another factor may be the growing availability of cheaper generic medications.
When brand-name drugs lose patent protection, the Bureau of Labor Statistics eventually replaces them in its pricing sample with lower-cost generic alternatives, which can pull the prescription drug index lower.
A wave of major medications has lost exclusivity over the past year, potentially adding further downward pressure.
RELATED: NEW: Inflation Makes Biggest Move Since 2020
The federal prescription drug index also measures more than the sticker price set by drugmakers. It tracks what pharmacies actually receive, including payments from consumers, insurers and Medicare Part D.
That means falling prices can reflect better negotiated deals, greater use of generics or lower out-of-pocket costs rather than only direct price cuts from pharmaceutical companies.
Whatever combination of factors is driving it, the result is hard to ignore: prescription drug prices are falling at a pace Americans have not seen since the early 1960s, and the Trump White House is wasting no time claiming the win.
